BrightPath Biotherapeutics Co., Ltd.
Supplementary Information for the 21st Issuance of Stock Acquisition Rights
BP issues stock acquisition rights as funding for the Phase I clinical trial of BP2202 in the United States. Potential issued shares: 34,500,000 shares; dilution: 24.84%; planned funds: 1,952 million yen. Exercise period: 2026/10/6–2027/10/6. Grants for exercise suspension, acquisition, and buyback, with a 3% discount. Use of funds: BP2202-related costs, other business operating funds, and new pipeline development costs. Cash and cash equivalents are about 1,580 million yen as of end of June 2026 to secure additional funds.
Key Figures
- 潜在発行株数: 34,500,000 shares
- 希薄化率: 24.84%
- 調達予定金額: 1,952 百万円
AI要約
Overview of Capital Policy
This supplementary document explains the purpose, terms, and use of funds for funding through the issuance of the 21st stock acquisition rights. Funds will be used for BP2202’s US Phase I clinical trial costs, other operating funds, and new pipeline development costs. To limit dilution, exercise suspension, acquisition, and buyback provisions are included. The discount rate is set at 3% to balance appropriate risk adjustment and effectiveness.
Impact of Funding and Outlook
As of the end of June 2026, cash and cash equivalents stood at 1,580 million yen. Additional funding is deemed necessary to progress BP2202’s clinical trials as planned, and staged financing will be carried out using stock acquisition rights. To mitigate dilution, provisions for exercise suspension, acquisition, and discount are set. Depending on funding adequacy and expenditure timing, future financing methods will be considered and disclosed.
BrightPath Biotherapeutics Co., Ltd.
Company overview · Stock price · Financial data · All IR
